Hide metadata

dc.contributor.authorDahm, Anders E
dc.contributor.authorIversen, Nina
dc.contributor.authorBirkenes, Baard
dc.contributor.authorRee, Anne H
dc.contributor.authorSandset, Per M
dc.date.accessioned2015-10-09T02:08:40Z
dc.date.available2015-10-09T02:08:40Z
dc.date.issued2006
dc.identifier.citationBMC Cardiovascular Disorders. 2006 Oct 09;6(1):40
dc.identifier.urihttp://hdl.handle.net/10852/46587
dc.description.abstractBackground Hormone therapy, oral contraceptives, and tamoxifen increase the risk of thrombotic disease. These compounds also reduce plasma content of tissue factor pathway inhibitor-1 (TFPI), which is the physiological inhibitor of the tissue factor pathway of coagulation. The current aim was to study if estrogens and estrogen receptor (ER) modulators may inhibit TFPI production in cultured endothelial cells and, if so, identify possible mechanisms involved. Methods Human endothelial cell cultures were treated with 17β-estradiol (E2), 17α-ethinylestradiol (EE2), tamoxifen, raloxifene, or fulvestrant. Protein levels of TFPI in cell media and cell lysates were measured by an enzyme-linked immunosorbent assay, and TFPI mRNA levels were assessed by quantitative PCR. Expression of ERα was analysed by immunostaining. Results All compounds (each in a concentration of 10 nM) reduced TFPI in cell medium, by 34% (E2), 21% (EE2), 16% (tamoxifen), and 28% (raloxifene), respectively, with identical inhibitory effects on cellular TFPI levels. Expression of TFPI mRNA was principally unchanged. Treatment with fulvestrant, which was also associated with down-regulation of secreted TFPI (9% with 10 nM and 26% with 1000 nM), abolished the TFPI-inhibiting effect of raloxifene, but not of the other compounds. Notably, the combination of 1000 nM fulvestrant and 10 nM raloxifene increased TFPI secretion, and, conversely, 10 nM of either tamoxifen or raloxifene seemed to partly (tamoxifen) or fully (raloxifene) counteract the inhibitory effect of 1000 nM fulvestrant. The cells did not express the regular nuclear 66 kDa ERα, but instead a 45 kDa ERα, which was not regulated by estrogens or ER modulators. Conclusion E2, EE2, tamoxifen, raloxifene, and fulvestrant inhibited endothelial production of TFPI by a mechanism apparently independent of TFPI transcription.
dc.language.isoeng
dc.rightsDahm et al.
dc.rightsAttribution 2.0 Generic
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/
dc.titleEstrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1
dc.typeJournal article
dc.date.updated2015-10-09T02:08:40Z
dc.creator.authorDahm, Anders E
dc.creator.authorIversen, Nina
dc.creator.authorBirkenes, Baard
dc.creator.authorRee, Anne H
dc.creator.authorSandset, Per M
dc.identifier.doihttp://dx.doi.org/10.1186/1471-2261-6-40
dc.identifier.urnURN:NBN:no-50768
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/46587/1/12872_2006_Article_131.pdf
dc.type.versionPublishedVersion
cristin.articleid40


Files in this item

Appears in the following Collection

Hide metadata

Attribution 2.0 Generic
This item's license is: Attribution 2.0 Generic